Author

Molina Matias

OpenAlex ID: A5025461663

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

2020 · Javier Cortes, David W Cescon, et al. · The Lancet · 1,797

Works count: 1

Citation count: 1,797

H-index: 1

I10-index: 1